Taking a closer look at Primes GLP-1 Year-2 cost-of-care findings David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing research Last week, Prime Therapeutics (Prime) released the latest data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, which showed individuals who newly started the drugs for weight loss experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity
These include ampicillin-susceptible strains of Haemophilus influenzae, penicillin-resistant strains of Staphylococcus aureus, -lactamase-producing strains of Moraxella catarrhalis, multidrug-resistant strains of Acinetobacter baumannii and Stenotrophomonas maltophilia, and strains of organisms resistant to other tetracyclines
Have you tried the new ones yet
La encuesta nacional de micronutrientes 2024 revel que, entre los nios de 0 a 6 aos, el 6.4 % tiene sobrepeso y un 4 % obesidad
:max_bytes(150000):strip_icc():focal(725x523:727x525)/smoothie-king-glp-1-102824-b4834de425734e4e9fe403db8e2c1fc1.jpg)
